A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome
DNLI-E-0002
Phase 2 other active
Quick answer
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome for Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II]) is a Phase 2 program (other) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])
- Phase
- Phase 2
- Modality
- other
- Status
- active